Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanoliposomal irinotecan plus Cadonilimab in second-line extensive-stage small cell lung cancer
ChiCTR2400087003Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jul 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan and cadonilimab in small cell lung cancer (SCLC), sponsored by Shandong Cancer Hospital. Primary endpoint: objective response rate. Started Jul 2024; status: recruiting.
02
Drugs
nanoliposomal irinotecancadonilimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400087003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087003.